Limited information indicates that maternal doses of buspirone up to 45 mg daily produce low levels in milk. Because no information is available on the long-term use of buspirone during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. A woman was taking buspirone 15 mg 3 times daily during pregnancy and postpartum. On day 13 postpartum, buspirone was undetectable in breastmilk by HPLC assay (limit of detection and time of sample not stated).[1]
Women taking buspirone 7.5 to 30 mg twice daily donated milk samples to a human milk repository. Levels of buspirone and its active metabolite 1-(2-pyrimidinyl) piperazine were measured. Buspirone was not detected (quantification limit not stated) in any samples, but the metabolite was found in low levels. The relative infant dose was estimated to be in the range of 0.21 to 2.17%.[2]
Infant Levels. In the exclusively breastfed infant of a mother who was taking buspirone 15 mg 3 times daily, buspirone was undetectable in the infant's serum by HPLC assay (limit of detection and time of sample not stated) on days 13 and 21 postpartum.[1]
Effects in Breastfed Infants
Possible drug-induced seizure-like activity and cyanosis occurred in a breastfed 3-week-old whose mother was taking buspirone 15 mg 3 times daily as well as fluoxetine and carbamazepine during pregnancy and breastfeeding. The authors thought that this reaction, if drug induced, was most likely caused by fluoxetine.[1]
One exclusively breastfed 11-week-old infant was breastfed during maternal therapy with buspirone 10 mg daily and venlafaxine 300 mg daily. No adverse reactions were reported by the mother or in the medical records.[3]
Effects on Lactation and Breastmilk
Buspirone increases serum prolactin.[4-7] Galactorrhea was reported in a woman taking venlafaxine after buspirone was added to her regimen. However, when buspirone was discontinued, galactorrhea persisted.[8] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
Brent NB, Wisner KL. Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. Clin Pediatr (Phila) 1998;37:41-4. [PubMed: 9475699]
2.
Krutsch KE, Datta P, Stark A, et al. Transfer of the non-sedating anxiolytic buspirone into human milk. Breastfeed Med 2023;18:A9. doi:10.1089/bfm.2023.29253.abstracts [CrossRef]
3.
Newport DJ, Ritchie JC, Knight BT, et al. Venlafaxine in human breast milk and nursing infant plasma: Determination of exposure. J Clin Psychiatry 2009;70:1304-10. [PubMed: 19607765]
4.
Bridge MW, Marvin G, Thompson CE, et al. Quantifying the 5-HT1a agonist action of buspirone in man. Psychopharmacology (Berl) 2001;158:224-9. [PubMed: 11713611]
5.
Gómez-Gil E, Navinés R, Martínez De Osaba, MJ, et al. Hormonal responses to the 5-HT1a agonist buspirone in remitted endogenous depressive patients after long-term imipramine treatment. Psychoneuroendocrinology 2010;35:481-9. [PubMed: 19762159]
6.
Maskall DD, Zis AP, Lam RW, et al. Prolactin response to buspirone challenge in the presence of dopaminergic blockade. Biol Psychiatry 1995;38:235-9. [PubMed: 8547445]
7.
Navinés R, Gómez-Gil E, Martin-Santos R, et al. Hormonal response to buspirone is not impaired in major depression. Hum Psychopharmacol 2007;22:389-95. [PubMed: 17563921]
8.
Sternbach H. Venlafaxine-induced galactorrhea. J Clin Psychopharmacol 2003;23:109-10. [PubMed: 12544389]
Substance Identification
Substance Name
Buspirone
CAS Registry Number
36505-84-7
Drug Class
Breast Feeding
Lactation
Milk, Human
Anti-Anxiety Agents
Serotonin Agonists
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
